Physical and Chemical Inactivators Evaluation for the Puumala Virus Vaccine Technology Development

Relevance. Hemorrhagic fever with renal syndrome (HFRS) is leading among natural focal human diseases in Russia, the causative agents of which - orthohantaviruses - belong to the order Bunyavirales, family Hantaviridae. More than 98% of HFRS cases in Russia are caused by the Puumala virus. It is a serious zoonosis for which there is still no specific treatment. The WHO has not approved a vaccine. The aim of this study was to investigate the effect of formaldehyde, β-propiolactone, hydrogen peroxide, ultraviolet rays, gamma irradiation and thermal inactivation on the immunogenic activity of inactivated vaccine preparations against HFRS Materials and methods. To achieve this aim, experimental vaccine preparations based on the PUU-TKD/VERO strain of Puumala virus were prepared and inactivated using the methods described above. The time intervals required for complete inactivation of the virus were determined, and the effects of the inactivators on viral RNA and immunogenic activity of the vaccine preparations were evaluated in BALB/c mouse and Syrian hamster models. Results. According to our results, vaccine preparations inactivated by different chemical and physical methods, which differ significantly in the mechanism of the mechanism of interaction with the virus, show no significant differences in immunogenic activity, except for thermal inactivation. Conclusion. A certain advantage of β-propiolactone is the short virus inactivation time, its complete degradation into non-toxic compounds within a few hours, and the reduction of total protein content after sterilization filtration, which is probably due to less aggregation of virus particles and cellular proteins

1. Kruger DH, Figueiredo LTM, Song JW, et al. Hantaviruses—globally emerging pathogens. Journal of clinical virology. 2015;64:128–136. doi: 0,1016/j.jcv.2014.08.033

2. Parvate A, Williams EP, Taylor MK, et al. Diverse Morphology and Structural Features of Old and New World Hantaviruses. Viruses. 2019;11(9):862. doi: 10,3390/v11090862

3. Modern technologies for the construction of vaccines for the prevention of hantavirus fever: Modern vaccines: development technologies and applications. Ed.: Tkachenko EA, Dzagurova TK, Tkachenko PE, Ishmukhametov AA. M.: Remedium Group LLC; 2017. P. 103–147 (In Russ.).

4. Jagannathan S, Gandhi PR, Vijayakumar R. Kinetics analysis of beta-propiolactone with tangential flow filtration (TFF). Journal of Biological Sciences. 2013;13(6):521–527. doi: 10,3923/jbs.2013.521.527

5. Sergeev VA, Nepoklonov EA, Aliper TI. Virusy i virusnye vakciny. M.: Biblionika, 2007. Р. 524 (In Russ.).

6. Li N, Qiao QL, Guo HF, et al. Evaluation of immunogenicity and protective efficacy of a novel Senecavirus A strain-based inactivated vaccine in mice. Research in Veterinary Science. 2022;142:133–140. doi: 10,1016/j.rvsc.2021.12.010

7. Zhou Y, Hu X, Chen R, et al. Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines. Vaccine. 2022; 40(28):3843-3850 doi: 10,1016/j.vaccine.2022.05.036

8. Berber E, Çanakoğlu N, Tonbak Ş, et al. Development of a protective inactivated vaccine against Crimean–Congo hemorrhagic fever infection. Heliyon. 2021;7(10). doi: 10,1016/j.heliyon.2021.e08161.

9. Chen H, Xie Z, Long R, et al. Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques. Molecular Therapy-Methods & Clinical Development. 2021;23:P 108–118. doi: 10,1016/j.omtm.2021.08.005

10. Tkachenko EA, Ishmukhametov AA, Dzagurova TK, et al. Razrabotka eksperimental’no-promyshlennoj tekhnologii proizvodstva vakciny dlya profilaktiki gemorragicheskoj lihoradki s pochechnym sindromom. Remedium. ZHurnal o rossijskom rynke lekarstv i medicinskoj tekhnike. 2015;6:47–53 (In Russ.).

11. Egorova MS, Kurashova SS, Dzagurova TK, et al. Effect of Virus-Inactivating Agents on the Immunogenicity of Hantavirus Vaccines against Hemorrhagic Fever with Renal Syndrome. Applied Biochemistry and Microbiology. 2020;56: 940–7. doi: 10,1134/S0003683820090045

12. Lei S, Gao X, Sun Y, et al. Gas chromatography-mass spectrometry method for determination of β-propiolactone in human inactivated rabies vaccine and its hydrolysis analysis. Journal of Pharmaceutical Analysis. 2018;8(6):373–7. doi: 10,1016/j.jpha.2018.06.003

13. Ronchi GF, Testa L, Iorio M, et al. Immunogenicity and safety studies of an inactivated vaccine against Rift Valley fever. Acta Tropica. 2022;232:106498. doi: 10,1016/j.actatropica. 2022.106498

14. Li A, Dai X, Chen L, et al. Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice. Biosafety and Health. 2022;4(1):45–52. doi: 10,1016/j.bsheal.2021.12.008

15. Kurashova SS, Ishmukhametov AA, Egorova MS, et al. Comparative Characteristics of Inactivation Agents for HFRS Vaccine Development. Epidemiology and Vaccinal Prevention. 2018;17(4):26–9 (In Russ.). doi: 10,31631/2073-3046-2018-17-4-26-29

16. Uittenbogaard JP, Zomer B, Hoogerhout P, et al. Reactions of β-propiolactone with nucleobase analogues, nucleosides, and peptides implications for the inactivation of viruses. Journal of Biological Chemistry. 2011;286(42):36198–36214. doi: 10,1074/jbc.M111.279232

17. Walker JM, Raué HP, Slifka MK. Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine. Journal of Virology. 2012;86(24):13735–13744. doi: 10,1128/JVI.02178-12

18. Archana T, Poer DeRaad D, Slifka M, et al. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Vaccine. 2019;37(30):4214–4221. doi: 10,1016/j.vaccine.2018.12.020

19. Abd-Elghaffar AA, Ali AE, Boseila AA, et al. Inactivation of rabies virus by hydrogen peroxide. Vaccine. 2016;34(6):798–802. doi: 10,1016/j.vaccine.2015.12.041

20. Termini J. Hydro peroxide - induced DNA damage and mutations. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2000;450(1–2):107–124. doi: 10,1016/s0027-5107(00)00019-1

21. Perdiz D, Gróf P, Mezzina M, et al. Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells possible role of dewar photoproducts in solar mutagenesis. Journal of Biological Chemistry. 2000;275(35):26732–26742. doi: 10,1074/jbc.M001450200

22. Tanaka T, Nogariya O, Shionoiri N, et al. Integrated molecular analysis of the inactivation of a non-enveloped virus, feline calicivirus, by UV-C radiation. Journal of bioscience and bioengineering. 2018;126(1):63–8. doi:10,1016/j.jbiosc.2018.01.018

23. Vaidya V, Dhere R, Agnihotri S, et al. Ultraviolet-C irradiation for inactivation of viruses in foetal bovine serum. Vaccine. 2018;36(29):4215–4221. doi: 10,1016/j.vaccine.2018.06.008

24. Campbell C. H. Immunogenicity of bluetongue virus inactivated by gamma irradiation. Vaccine. 1985;3(5):401–6. doi: 10,1016/0264-410x(85)90131-8

25. Marennikova SS, Macevič GR. Experimental study of the role of inactivated vaccine in two-step vaccination against smallpox. Bulletin of the World Health Organization. 1975;52(1):51.

26. Elliott LH, McCormick JB, Johnson KM. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. Journal of Clinical Microbiology. 1982;16(4):704–8. doi: 10,1128/jcm.16.4.704-708.1982

27. Furuya Y. Return of inactivated whole‐virus vaccine for superior efficacy. Immunology and cell biology. 2012;90(6):571–8. doi: 10,1038/icb.2011.70

28. Dzagurova TK, Tkachenko EA, Ishmukhametov AA, et al. Virus strain for producing vaccine drugs against hemorrhagic fever with renal syndrome (options). Patent IPC C12N7/00, No. 2683508C1. Russia. 2019 (In Russ.).

29. Egorova MS, Kurashova SS, Ishmukhametov AA, et al. Real-time PCR assay development for the control of vaccine against hemorrhagic fever with renal syndrome. Voprosy Virusologii. 2021;66(1):65–73 (In Russ.). doi: 10,36233/0507-4088-30

30. Waterborg JH. The Lowry method for protein quantitation. The protein protocols handbook. 2009;7–10. doi: 10,1385/0-89603-062-8:1